InsiderSignal.AI

InsiderSignal.ai

GENB - Generate Biomedicines, Inc.

Insider Purchase by Afeyan Noubar (Dir, 10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Afeyan Noubar, serving as Dir, 10% owner at Generate Biomedicines, Inc. (GENB), purchased 4,687,500 shares at $16.00 per share, for a total transaction value of $75,000,000.00. Following this transaction, Afeyan Noubar now holds 62,673,117 shares of GENB.

This purchase represents a 8.00% increase in Afeyan Noubar's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 2, 2026, meaning the disclosure happened on the same day as the trade.

Generate Biomedicines, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Afeyan Noubar

Dir, 10%

Noubar Afeyan is a prominent entrepreneur and venture capitalist who serves as Co-Founder and Chairman of Generate:Biomedicines, as well as Founder and CEO of Flagship Pioneering, a leading life sciences venture capital firm[[1]](https://generatebiomedicines.com/media-center/generatebiomedicines-expands-board-of-directors). With a Ph.D. in chemical engineering, Afeyan has built a distinguished career at the intersection of science and entrepreneurship, founding and leading multiple biotech ventures. He holds approximately 57.7% ownership in Generate:Biomedicines, the Somerville, Massachusetts-based company that uses artificial intelligence to revolutionize drug discovery and create new protein-based therapeutics[[4]](https://www.boursorama.com/bourse/actualites/generate-biomedicines-soutenue-par-flagship-vise-une-valorisation-de-2-2-milliards-de-dollars-lors-de-son-introduction-en-bourse-aux-etats-unis-764c16fcd6c1f6968b57572b18351c2a). As a director and 10% public owner of Generate:Biomedicines, Afeyan has been actively engaged in the company's recent capital activities[[2]](https://www.sahmcapital.com/news/content/noubar-afeyan-director-acquires-generate-biomedicines-common-shares-2026-03-03). In February 2026, Afeyan received a stock option covering 29,561 shares vesting in February 2027, and Flagship Pioneering-affiliated funds under his direction purchased 4.6 million shares of common stock at $16.00 per share[[3]](https://www.stocktitan.net/sec-filings/GENB/form-4-generate-biomedicines-inc-insider-trading-activity-91a4d7654629.html). His leadership extends beyond Generate:Biomedicines through Flagship Pioneering, where he directs a portfolio of innovative life sciences companies and maintains significant influence over the firm's strategic investments and operations.

View full insider profile →

Trade Price

$16.00

Quantity

4,687,500

Total Value

$75,000,000.00

Shares Owned

62,673,117

Trade Date

Monday, March 2, 2026

48 days ago

SEC Filing Date

Monday, March 2, 2026

HEALTHCAREBIOTECHNOLOGY

About Generate Biomedicines, Inc.

Company Overview

No company information available
View news mentioning GENB

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4441052

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime